Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial Infarction: Economic Evaluation of the Acute Infarction Ramipril Efficacy (AIRE) Study for Germany from the Perspective of Statutory Health Insurance

By Schädlich P.K.  

PharmacoEconomics, Vol. 14, Iss. 6, 1998-12 ,pp. : 653-669

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular Events: Economic Evaluation of the HOPE (Heart Outcomes Prevention Evaluation) Study for Germany from the Statutory Health Insurance Perspective

By Peter K. Schädlich  

PharmacoEconomics, Vol. 22, Iss. 15, 2004-01 ,pp. : 955-973

Adis International

Access to resources Recommend Favorite

Economic Evaluation of Enoxaparin for Anticoagulation in Early Cardioversion of Persisting Nonvalvular Atrial Fibrillation: A Statutory Health Insurance Perspective from Germany

By Schädlich Peter K.  

American Journal of Cardiovascular Drugs, Vol. 7, Iss. 3, 2007-01 ,pp. : 199-217

Adis International

Access to resources Recommend Favorite

The Effect of Ramipril Therapy on Cytokines and Parameters of Incipient Diabetic Nephropathy in Patients with Type 1 Diabetes Mellitus

By Janickova Zdarska D   Zavadova E   Kvapil M  

The Journal of International Medical Research, Vol. 35, Iss. 3, 2007-05 ,pp. : 374-383

Field House Publishing

Access to resources Recommend Favorite

Moxonidine and Ramipril in Patients with Hypertension and Obstructive Pulmonary Disease

By Feuring M.  

Clinical Drug Investigation, Vol. 20, Iss. 1, 2000-07 ,pp. : 19-24

Adis International

Access to resources Recommend Favorite